original ) (raw )PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells
Tugba Taskin Tok
European journal of medicinal chemistry, 2019
View PDFchevron_right
Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer
Tugba Taskin Tok
European journal of medicinal chemistry, 2020
View PDFchevron_right
Prodrugs For Nitroreductase Based Cancer Therapy- 1 Metabolite Profile, Cell Cytotoxicity and Molecular Modeling Interactions of Nitro Benzamides with Ssap-NtrB
Esra Tokay
Medicinal chemistry (Shariqah (United Arab Emirates)), 2017
View PDFchevron_right
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT)
Michael P Hay
Bioorganic & Medicinal Chemistry Letters, 1999
View PDFchevron_right
Structure−Activity Relationships for 4-Nitrobenzyl Carbamates of 5-Aminobenz[ e ]indoline Minor Groove Alkylating Agents as Prodrugs for GDEPT in Conjunction with E. c oli Nitroreductase
Michael P Hay
Journal of Medicinal Chemistry, 2003
View PDFchevron_right
Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A
Alexandra Mowday
Biochemical Pharmacology, 2013
View PDFchevron_right
Kinetic and Structural Characterisation of Escherichia coli Nitroreductase Mutants Showing Improved Efficacy for the Prodrug Substrate CB1954
Paul Race
Journal of Molecular Biology, 2007
View PDFchevron_right
Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications
Maria Abbattista
Pharmaceuticals, 2022
View PDFchevron_right
Nitroreductase-activated nitric oxide (NO) prodrugs
Kavita Sharma
Bioorganic & Medicinal Chemistry Letters, 2013
View PDFchevron_right
Design, synthesis, molecular docking, and biological evaluation ofN-methyl-3-nitro-4-(nitromethyl)-4H-chromen-2-amine derivatives as potential anti-cancer agents
A Parthiban
Medicinal Chemistry Research, 2014
View PDFchevron_right
Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities
Jan Wasley
Bioorganic & Medicinal Chemistry Letters, 2011
View PDFchevron_right
Molecular docking studies of novel nitrophenyl inhibitor against aldose reductase
Dr. Murtaza Hajoori
International Journal of Research and Analytical Reviews, 2019
View PDFchevron_right
Nitroaryl Phosphoramides as Novel Prodrugs for E. coli Nitroreductase Activation in Enzyme Prodrug Therapy
Patrick Browne
Journal of Medicinal Chemistry, 2003
View PDFchevron_right
Synthesis and anticancer activity studies of ?-aminoalkylated conjugated nitroalkenes
namrata rastogi
Organic & Biomolecular Chemistry, 2006
View PDFchevron_right
Metabolic Activation of the Antitumor Drug 5-(Aziridin-1-yl)-2,4-Dinitrobenzamide (CB1954) by NO Synthases
Nuala Helsby
Chemical Research in Toxicology, 2008
View PDFchevron_right
Nitroreductase: A Prodrug-Activating Enzyme for Cancer Gene Therapy
David Kerr
Clinical and Experimental Pharmacology and Physiology, 2004
View PDFchevron_right
Metabolic Activation of the Antitumor Drug 5-(Aziridin-1-yl)-2,4-Dmitrobenzamide (CB1954) by NO Synthases
Yves Frapart
Chemical Research in Toxicology, 2008
View PDFchevron_right
Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954
Paul Race
Cancer Research
View PDFchevron_right
Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy
Michael P Hay
Bioorganic & Medicinal Chemistry, 2005
View PDFchevron_right
Process Development and Protein Engineering Enhanced Nitroreductase-Catalyzed Reduction of 2-Methyl-5-nitro-pyridine
Ahir Pushpanath
Organic Process Research & Development, 2020
View PDFchevron_right
Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4
Peter Wardman
Molecular Cancer Therapeutics, 2006
View PDFchevron_right
Synthesis, biological and electrochemical evaluation of novel nitroaromatics as potential anticancerous drugs
Bushra Mirza
Bioelectrochemistry, 2015
View PDFchevron_right
Synthesis, Biological Evaluation, and Docking Studies of N-Substituted Acetamidines as Selective Inhibitors of Inducible Nitric Oxide Synthase
Mario Felaco
Journal of Medicinal Chemistry, 2009
View PDFchevron_right
Generation of Escherichia Coli Nitroreductase Mutants Conferring Improved Cell Sensitization to the Prodrug CB19541
Paul Race
2003
View PDFchevron_right
Design and Synthesis of Some Novel Aromatic Amide Derivatives of Nilutamide as In Vitro Anticancer Agents
Sirassu Narasimha
ChemistrySelect, 2020
View PDFchevron_right
Optimised synthesis of a nitroCBI hypoxia-activated prodrug with substantial anticancer activity
Shangjin Yang
Tetrahedron, 2019
View PDFchevron_right
Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells
Magdalena Niemira
Biochemical Pharmacology, 2012
View PDFchevron_right
Activation of the c-Jun N-terminal Kinase/Activating Transcription Factor 3 (ATF3) Pathway Characterizes Effective Arylated Diazeniumdiolate-Based Nitric Oxide-Releasing Anticancer Prodrugs
Joseph Saavedra
Journal of Medicinal Chemistry, 2011
View PDFchevron_right
Biological evaluation of selected metronidazole derivatives as anti-nitroreductase via in silico approach
Moriam Adeoye
View PDFchevron_right